A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy. Issue 4 (August 2015)

• Record Type: Journal Article
• Authors: Pertega‐Gomes, Nelma; Felisbino, Sergio; Massie, Charlie E; Vizcaino, Jose R; Coelho, Ricardo; Sandi, Chiranjeevi; Simoes‐Sousa, Susana; Jurmeister, Sarah; Ramos‐Montoya, Antonio; Asim, Mohammad; Tran, Maxine; Oliveira, Elsa; Lobo da Cunha, Alexandre; Maximo, Valdemar; Baltazar, Fatima; Neal, David E; Fryer, Lee GD
• Is Part Of: Journal of pathology. Volume 236:Issue 4(2015)
• Page Start: 517
• Page End: 530
• Publication Date: 2015-08
• Subjects: Pathology -- Periodicals; 616.07
• DOI: 10.1002/path.4547
• Languages: English
• ISSNs: 0022-3417

Abstract

<abstract abstract-type="main" id="path4547-abs-0001"> <title>Abstract</title> <p id="path4547-para-0001">Metabolic adaptation is considered an emerging hallmark of cancer, whereby cancer cells exhibit high rates of glucose consumption with consequent lactate production. To ensure rapid efflux of lactate, most cancer cells express high levels of monocarboxylate transporters (MCTs), which therefore may constitute suitable therapeutic targets. The impact of MCT inhibition, along with the clinical impact of altered cellular metabolism during prostate cancer (PCa) initiation and progression, has not been described. Using a large cohort of human prostate tissues of different grades, <italic>in silico</italic> data, <italic>in vitro</italic> and <italic>ex vivo</italic> studies, we demonstrate the metabolic heterogeneity of PCa and its clinical relevance. We show an increased glycolytic phenotype in advanced stages of PCa and its correlation with poor prognosis. Finally, we present evidence supporting MCTs as suitable targets in PCa, affecting not only cancer cell proliferation and survival but also the expression of a number of hypoxia‐inducible factor target genes associated with poor prognosis. Herein, we suggest that patients with highly glycolytic tumours have poorer outcome, supporting the notion of targeting glycolytic tumour cells in prostate cancer through the use of MCT inhibitors. © 2015 Authors. <italic>Journal of Pathology published</italic> by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.</p> </abstract>